Genomic Vision at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels from 25 to 26 October 2023
October 24 2023 - 12:00PM
Business Wire
- Genomic Vision will present its innovative solutions and
introduce its new HexaCard® service at the 30th Annual ESGCT
Congress in Brussels.
- HexaCard® service enables the simultaneous analysis of six
critical parameters to streamline cell line development, enhance
productivity, and reduce costs.
- Participation in the ESGCT Congress enables Genomic Vision
to introduce its advanced technology to the European pharmaceutical
market, fostering collaborations and industry
advancements.
Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”)
(Paris:GV), a Euronext-listed biotechnology company that
develops products and services for the highly accurate
characterization of transformed cells is pleased to announce its
participation in the 30th Annual European Society of Gene and Cell
Therapy (ESGCT) Congress in Brussels, where GV will present its
work in bioproduction and introduce its recently launched HexaCard®
service.
Since the summer launch of HexaCard®, Genomic Vision has
witnessed significant interest from industrial players. This new
service, designed to revolutionize cell line development, allows
the simultaneous analysis of six key parameters, creating a unique
identity card for each cell. This comprehensive analysis ensures
the selection of the most suitable clones, thereby enhancing
productivity and stability while reducing timelines and costs.
The HexaCard® service is poised to be a game-changer for the
bioproduction industry, as it empowers pharmaceutical and biotech
companies to streamline their cell line development processes. By
providing a comprehensive characterization of transformed cells in
a single assay, HexaCard® facilitates quicker and more
cost-effective decision-making. It offers a level of precision that
was previously unattainable, making it an invaluable asset for
those involved in bioproduction and gene and cell therapy.
Genomic Vision's presence at the 30th Annual ESGCT Congress
underscores its commitment to introducing this transformative
technology to the European pharmaceutical and biotech markets. The
company looks forward to engaging with industry professionals,
sharing insights, and building collaborations during the event, and
contribute to the advancement of gene therapy, cell therapy, and
bioproduction on a global scale. This congress serves as a valuable
opportunity for Genomic Vision to engage with peers, foster
collaborations, and ultimately drive innovation in the field.
Prakhar Bisht, PhD, Principal Scientist at Genomic Vision,
shared his insights on this breakthrough service, saying, "Our
presence at the ESGCT congress not only delineates our commitment
to support Biomanufacturing and Cell & Gene therapy, but also
to introduce our HexaCard® platform for services to a wider
audience. Our presence at this congress allows us to share our
cutting edge solutions with fellow experts and industry
leaders."
ABOUT THE 30TH ANNUAL EUROPEAN SOCIETY OF CELL AND GENE
THERAPY (ESGCT) CONGRESS
The 30th Annual European Society of Gene and Cell Therapy
(ESGCT) Congress, hosted in Brussels from 24 to 27 October 2023,
serves as a pivotal gathering for professionals in the field of
gene and cell therapy. This prestigious event brings together
scientists, researchers, industry leaders, and academia, providing
an ideal platform for the exchange of knowledge and the exploration
of cutting-edge innovations in the sector. With a focus on the
latest advancements in gene and cell therapy, the ESGCT Congress
provides a unique opportunity for attendees to stay at the
forefront of industry developments and establish collaborations
that drive progress in the field.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies. Genomic
Vision’s molecular combing technology has further applications in
drug development of agents targeting DNA replication and damage
response mechanisms, visualizing DNA replication kinetics and
telomere length maintenance. Genomic Vision, based near Paris in
Bagneux, is a public company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with its Financing
partner.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market,
which could create downward pressure on the share price as well as
a dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024213296/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
NewCap France Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Visionary (NASDAQ:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Visionary (NASDAQ:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024